Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial
Posted inClinical Updates Wellness & Lifestyle

Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial

The VICTOR trial in stable HFrEF patients shows vericiguat does not significantly reduce the composite of cardiovascular death or heart failure hospitalization but lowers cardiovascular and all-cause mortality, highlighting its potential for mortality risk reduction.
Evaluating the Impact of Vitamin D3, Omega-3 Fatty Acids, and Home Exercise on Vertebral Fracture Prevention in Older Adults: Insights from the DO-HEALTH Trial
Posted inClinical Updates Wellness & Lifestyle

Evaluating the Impact of Vitamin D3, Omega-3 Fatty Acids, and Home Exercise on Vertebral Fracture Prevention in Older Adults: Insights from the DO-HEALTH Trial

The DO-HEALTH trial found that vitamin D3 and omega-3 supplementation did not reduce vertebral fracture rates in healthy seniors, while a simple home exercise program lowered fracture incidence in women and slowed fracture progression overall, highlighting exercise’s potential role in vertebral fracture prevention.
Posted inClinical Updates Wellness & Lifestyle

Methylcobalamin Significantly Reduces Severe Hand-Foot Syndrome in HER2 Negative Early Breast Cancer Patients Receiving Capecitabine: Results from a Phase 3 Randomised Trial

Oral methylcobalamin notably decreased the incidence of grade ≥2 hand-foot syndrome in patients with HER2 negative early breast cancer undergoing adjuvant capecitabine treatment, without added safety concerns, improving treatment adherence potential.
Posted inClinical Updates Wellness & Lifestyle

Efficacy of Liposomal Irinotecan Plus 5-FU/LV in Previously Treated Biliary Tract Cancer: Insights from Pooled NIFTY and NALIRICC Trials

A pooled analysis of NIFTY and NALIRICC trials demonstrates that liposomal irinotecan combined with 5-FU/leucovorin significantly improves progression-free survival and response rates in previously treated biliary tract cancer, with notable ethnic variations in toxicity profiles.